##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 4 (2025)

Prognostic value of health-related quality of life in patients with acute dyspnoea: a cohort study

Cite this as:
Swiss Med Wkly. 2025;155:3785
Published
15.04.2025

Summary

BACKGROUND: Self-reported health-related quality of life is an established prognostic tool in stable outpatients. However, its prognostic relevance in patients presenting with an acute onset of symptoms such as acute dyspnoea is largely unknown.

METHODS: This major unmet clinical need was addressed in a secondary analysis of a prospective study, enrolling patients presenting with acute dyspnoea to the emergency departments of two university hospitals in Switzerland. Self-reported health-related quality of life was obtained at presentation with the use of the generic EQ-5D tool and directly compared to the objective risk prediction marker N-terminal pro-B-type natriuretic peptide (NT-proBNP). The primary endpoint was all-cause mortality within 90 and 720 days. Cox proportional hazard regressions were performed with age, sex, history of heart failure, systolic blood pressure, haemoglobin, estimated glomerular filtration rate and NT-proBNP as predictors. Prognostic accuracies were calculated with the use of area under the receiver operating characteristics curve (AUC).

RESULTS: Among 1144 eligible patients (median age 74 years, 42% women, 52% acute heart failure), 7% died within 90 days and 28% within 720 days after presentation to the emergency department. The EQ-5D index was strongly associated with mortality. In adjusted Cox regression analyses, the hazard ratios of the EQ-5D index for 90- and 720-day mortality were 7.8 (95% confidence interval [CI] 3.4–17.9) and 5.0 (95% CI 3.3–7.6), respectively. Prognostic accuracies of the EQ-5D index for 90- and 720-day mortality were 0.68 and 0.65, and comparable to the prognostic accuracy of NT-proBNP (both AUCs: 0.69, p-value for comparison 0.915 and 0.121).

CONCLUSIONS: Self-reported health-related quality of life assessed by the generic EQ-5D tool provides moderate-to-high prognostic accuracy in patients presenting with acute dyspnoea to the emergency department and may aid physicians in risk stratification.

Trial registration: https://clinicaltrials.gov NCT01831115.

References

  1. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al.; American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012 Feb;185(4):435–52. 10.1164/rccm.201111-2042ST
  2. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, et al.; Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008 Feb;168(3):316–24. 10.1001/archinternmed.2007.83
  3. Wussler D, Michou E, Belkin M, Kozhuharov N, Diebold M, Gualandro DM, et al. Mortality prediction in acute heart failure: scores or biomarkers? Swiss Med Wkly. 2020 Aug;150(3334):w20320–20320. 10.4414/smw.2020.20320
  4. Christ M, Laule-Kilian K, Hochholzer W, Klima T, Breidthardt T, Perruchoud AP, et al. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol. 2006;48(9):1808–12. 10.1016/j.jacc.2006.07.037
  5. Christ M, Thuerlimann A, Laule K, Klima T, Hochholzer W, Perruchoud AP, et al. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur J Clin Invest. 2007 Nov;37(11):834–41. 10.1111/j.1365-2362.2007.01871.x
  6. Kozhuharov N, Sabti Z, Wussler D, Nowak A, Badertscher P, Twerenbold R, et al.; BASEL V Investigators. Prospective validation of N-terminal pro B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure. Eur J Heart Fail. 2019 Jun;21(6):813–5. 10.1002/ejhf.1471
  7. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004 Feb;350(7):647–54. 10.1056/NEJMoa031681
  8. Miró Ò, Rossello X, Gil V, Martín-Sánchez FJ, Llorens P, Herrero-Puente P, et al.; ICA-SEMES Research Group. Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort Study. Ann Intern Med. 2017 Nov;167(10):698–705. 10.7326/M16-2726
  9. Wussler D, Kozhuharov N, Sabti Z, Walter J, Strebel I, Scholl L, et al. External Validation of the MEESSI Acute Heart Failure Risk Score: A Cohort Study. Ann Intern Med. 2019 Feb;170(4):248–56. 10.7326/M18-1967
  10. Alla F, Briançon S, Guillemin F, Juillière Y, Mertès PM, Villemot JP, et al.; EPICAL Investigators. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. Eur J Heart Fail. 2002 Jun;4(3):337–43. 10.1016/s1388-9842(02)00006-5 doi: https://doi.org/10.1016/S1388-9842(02)00006-5
  11. Moradi M, Daneshi F, Behzadmehr R, Rafiemanesh H, Bouya S, Raeisi M. Quality of life of chronic heart failure patients: a systematic review and meta-analysis. Heart Fail Rev. 2020 Nov;25(6):993–1006. 10.1007/s10741-019-09890-2
  12. Belkin M, Michou E, Mueller C. Letter by Belkin et al Regarding Article, “Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction”. Circulation. 2020 May;141(20):e820–1. 10.1161/CIRCULATIONAHA.120.045718
  13. Belkin M, Wussler D, Gualandro DM, Shrestha S, Strebel I, Goudev A, et al. Effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life among patients with acute heart failure. ESC Heart Fail. 2021 Oct;8(5):4218–27. 10.1002/ehf2.13543
  14. Belkin M, Wussler D, Michou E, Strebel I, Kozhuharov N, Sabti Z, et al. Prognostic Value of Self-Reported Subjective Exercise Capacity in Patients With Acute Dyspnea. JACC Adv. 2023 May;2(3):100342. 10.1016/j.jacadv.2023.100342
  15. Wussler D, Belkin M, Mueller C. Letter by Wussler et al Regarding Article, “Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?”. Circulation. 2023 Aug;148(7):619–619. 10.1161/CIRCULATIONAHA.123.064413
  16. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep;42(36):3599–726. 10.1093/eurheartj/ehab368
  17. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al.; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May;145(18):e895–1032. 10.1161/CIR.0000000000001063
  18. Rumsfeld JS, Alexander KP, Goff DC Jr, Graham MM, Ho PM, Masoudi FA, et al.; American Heart Association Council on Quality of Care and Outcomes Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, and Stroke Council. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation. 2013 Jun;127(22):2233–49. 10.1161/CIR.0b013e3182949a2e
  19. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208. 10.1016/0168-8510(90)90421-9
  20. Boczor S, Daubmann A, Eisele M, Blozik E, Scherer M. Quality of life assessment in patients with heart failure: validity of the German version of the generic EQ-5D-5L™. BMC Public Health. 2019 Nov;19(1):1464. 10.1186/s12889-019-7623-2
  21. Nagy KV, Merkely B, Rosero S, Geller L, Kosztin A, McNitt S, et al. Quality of life predicting long-term outcomes in cardiac resynchronization therapy patients. Europace. 2019 Dec;21(12):1865–75. 10.1093/europace/euz262
  22. Wussler D, Kozhuharov N, Tavares Oliveira M, Bossa A, Sabti Z, Nowak A, et al. Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. Clin Chem. 2019 Dec;65(12):1532–42. 10.1373/clinchem.2019.306787
  23. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JG, Kozhuharov N, et al.; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019 Jun;21(6):715–31. 10.1002/ejhf.1494
  24. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al.; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29(19):2388–442. 10.1093/eurheartj/ehn309
  25. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17(1):37–49. 10.1016/0022-3956(82)90033-4
  26. Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail. 2014 Oct;2(5):429–36. 10.1016/j.jchf.2014.04.006
  27. Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail. 2017 May;19(5):627–34. 10.1002/ejhf.785
  28. Therneau TM, Grambsch PM, Fleming TR. Martingale-Based Residuals for Survival Models. Biometrika. 1990;77(1):147–60. 10.2307/2336057 doi: https://doi.org/10.1093/biomet/77.1.147
  29. Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017 Apr;17(1):53. 10.1186/s12874-017-0332-6
  30. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep;44(3):837–45. 10.2307/2531595
  31. Janssen MF, Szende A, Cabases J, Ramos-Goñi JM, Vilagut G, König HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019 Mar;20(2):205–16. 10.1007/s10198-018-0955-5
  32. Rossello X, Miró Ò, Llorens P, Jacob J, Herrero-Puente P, Gil V, et al.; ICA-SEMES Research Group. Effect of Barthel Index on the Risk of Thirty-Day Mortality in Patients With Acute Heart Failure Attending the Emergency Department: A Cohort Study of Nine Thousand Ninety-Eight Patients From the Epidemiology of Acute Heart Failure in Emergency Departments Registry. Ann Emerg Med. 2019 Jun;73(6):589–98. 10.1016/j.annemergmed.2018.12.009
  33. Mahoney FI, Barthel DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965 Feb;14:61–5.
  34. Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017 Sep;19(9):1095–104. 10.1002/ejhf.822